Data / Drug companies / Cipla USA Inc.
Cipla USA Inc.: 268 products in the FDA NDC directory, labeler code 69097
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Cipla USA Inc. (labeler code 69097) lists 268 products in the FDA National Drug Code Directory, covering 108 finished drugs by generic name. By type: 267 prescription drugs, 1 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 21, 2026.
The request: Watch Cipla USA Inc. (FDA labeler code 69097): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 69097
- Products in commercial distribution
- 268
- Packages
- 496
- Finished drugs by generic name
- 108
- Prescription products
- 267
- Over the counter products
- 1
- Controlled substance products
- Schedule III 4, Schedule IV 2, Schedule V 16
- Flagged as original packager
- 256 of 256 products that carry the flag
- Started marketing in the last 12 months
- 17
- Products with a marketing end date set
- 3
- Earliest marketing start
- July 19, 2006
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 257 | 95.9% |
| New drug applications (NDA) | 8 | 3% |
| Biologics (BLA) | 2 | 0.7% |
| Authorized generics (NDA) | 1 | 0.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 267 | 99.6% |
| Over the counter drugs | 1 | 0.4% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 80 | 29.9% |
| Capsule | 51 | 19% |
| Tablet, film coated | 47 | 17.5% |
| Injection | 19 | 7.1% |
| Tablet, extended release | 16 | 6% |
| Injection, solution | 6 | 2.2% |
| For suspension | 5 | 1.9% |
| Inhalant | 4 | 1.5% |
| Solution | 4 | 1.5% |
| Powder | 3 | 1.1% |
| Injection, emulsion | 3 | 1.1% |
| Kit | 3 | 1.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Cyclosporine | 69097-292 | Emulsion | Generic drugs (ANDA) | September 21, 2026 |
| Pomalidomide | 69097-039 | Capsule | Generic drugs (ANDA) | August 30, 2026 |
| Pomalidomide | 69097-038 | Capsule | Generic drugs (ANDA) | August 30, 2026 |
| Pomalidomide | 69097-037 | Capsule | Generic drugs (ANDA) | August 30, 2026 |
| Pomalidomide | 69097-036 | Capsule | Generic drugs (ANDA) | August 30, 2026 |
| Fluticasone propionate and Salmeterol | 69097-663 | Powder | Generic drugs (ANDA) | July 27, 2026 |
| Fluticasone propionate and Salmeterol | 69097-662 | Powder | Generic drugs (ANDA) | July 27, 2026 |
| Fluticasone propionate and Salmeterol | 69097-661 | Powder | Generic drugs (ANDA) | July 27, 2026 |
| Albuterol | 69097-021 | Aerosol, metered | Generic drugs (ANDA) | April 22, 2026 |
| Dapagliflozin | 69097-389 | Tablet, film coated | Generic drugs (ANDA) | April 6, 2026 |
| Dapagliflozin | 69097-388 | Tablet, film coated | Generic drugs (ANDA) | April 6, 2026 |
| Nintedanib | 69097-641 | Capsule | Generic drugs (ANDA) | April 2, 2026 |
| Nintedanib | 69097-639 | Capsule | Generic drugs (ANDA) | April 2, 2026 |
| Liraglutide | 69097-910 | Injection, solution | Generic drugs (ANDA) | February 25, 2026 |
| Nypozi | 69097-430 | Injection | Biologics (BLA) | February 11, 2026 |
| Nypozi | 69097-429 | Injection | Biologics (BLA) | February 11, 2026 |
| Liraglutide | 69097-920 | Injection, solution | Generic drugs (ANDA) | January 22, 2026 |
| Ticagrelor | 69097-989 | Tablet, film coated | Generic drugs (ANDA) | October 29, 2025 |
| Glucagon | 69097-027 | Kit | Generic drugs (ANDA) | October 8, 2025 |
| Sertraline Hydrochloride | 69097-451 | Capsule | Generic drugs (ANDA) | July 17, 2025 |
| Sertraline Hydrochloride | 69097-438 | Capsule | Generic drugs (ANDA) | July 17, 2025 |
| Prucalopride | 69097-219 | Tablet, film coated | Generic drugs (ANDA) | June 25, 2025 |
| Prucalopride | 69097-218 | Tablet, film coated | Generic drugs (ANDA) | June 25, 2025 |
| Nilotinib | 69097-032 | Capsule | New drug applications (NDA) | June 18, 2025 |
| Nilotinib | 69097-031 | Capsule | New drug applications (NDA) | June 18, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.